期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤细胞疫苗的研究进展 被引量：2

下载PDF
导出
摘要 恶性肿瘤是威胁人类健康和生命的主要疾病之一,其发病率逐年增高,有效地治疗恶性肿瘤是一项长期而艰巨的任务。目前,常规的治疗恶性肿瘤的手术、放疗、化疗等手段尚不能达到满意的治疗效果,并且都伴有明显的毒副作用。
作者 黄文俊 曾晓荣
机构地区 泸州医学院心血管医学研究所
出处 《泸州医学院学报》 2012年第4期435-439,共5页 Journal of Luzhou Medical College
关键词 肿瘤细胞疫苗 恶性肿瘤 治疗效果 人类健康 毒副作用 发病率
分类号 R733.62 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献14

  • 1李国强,印洁,王学浩,孙倍成,俞悦.CD80 CD86和CD137L基因联合表达对小鼠肝癌种植模型肿瘤免疫原性的影响[J].中华肿瘤杂志,2006,28(7):490-493. 被引量：4
  • 2李国强,王学浩,印洁,俞悦.同时表达4-1BBL B7.1及B7.2三个共刺激分子基因小鼠肝癌细胞系的建立和意义[J].中国肿瘤临床,2006,33(22):1261-1264. 被引量：3
  • 3张学光 朱剑昆.共刺激分子及其在免疫应答中的作用[A].朱迅主编.免疫学新进展[C].北京:人民卫生出版社,2002.426.
  • 4Melero I, Bach N, Hellstrom KE, et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CIY28 co-stimulatory pathway. Eur J Immunol, 1998, 28:1116-1121.
  • 5Guinn BA, DeBenedette MA, Watts TH, et al. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol, 1999, 162 : 5003- 5010.
  • 6Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are to previously activated splenic T cells and inhibit activation- induced cell death. J Immunol, 1997, 158:2600-2609.
  • 7Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol, 1999, 162: 5037-5040.
  • 8Bernstein WB, Cox JH, Aronson N-E, et al. Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4 ( + ) T cells to HIV-infected persons. Clin Immunol, 2004, 111 : 262- 274.
  • 9Heyninck K, Kreike MM, Beyaert R. Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1. FEBS Lett, 2003, 536:135-140.
  • 10Nair A, Venkatraman M, Maliekal TT, et al. NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene, 2003, 22:50-58.

共引文献1

同被引文献50

  • 1杨化强,曹以诚.细胞因子和趋化因子作为DNA疫苗基因佐剂的研究进展[J].中南药学,2006,4(1):39-42. 被引量：1
  • 2Cheever MA,Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer:the first FDA-approved therapeutic cancer vaccine[J].Clinical Cancer Research,2011,(11):3520-3526.
  • 3Riedmann EM. Two years of Provenge[J].Hum Vaccin Immunother,2012,(04):505.
  • 4Madan RA,Gulley JL. Sipuleucel-T:harbinger of a new age of therapeutics for prostate cancer[J].Expert Review of Vaccines,2011,(02):141-150.
  • 5Parmiani G,Castelli C,Pilla L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients[J].Annals of Oncology,2007,(02):226-232.
  • 6Olivares J,Kumar P,Yu Y. Phase Ⅰ trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine[J].Clinical Cancer Research,2011,(01):183-192.
  • 7Okada H,Lieberman FS,Walter KA. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas[J].Journal of Traditional Medicines,2007,(19):67-77.
  • 8Slingluff CJ. The present and future of peptide vaccines for cancer:single or multiple,long or short,alone or in combination[J].Cancer Journal,2011,(05):343-350.
  • 9Becker JC,Andersen MH,Hofmeister-Muller V. Survivinspecific T-cell reactivity correlates with tumor response and patient survival:a phase-Ⅱ peptide vaccination trial in metastatic melanoma[J].Cancer Immunology, Immunotherapy,2012,(11):2091-2103.
  • 10Schwartzentruber DJ,Lawson DH,Richards JM. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma[J].New England Journal of Medicine,2011,(22):2119-2127.

引证文献2

二级引证文献7

泸州医学院学报
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部